Biogen's (NASDAQ: BIIB) multiple sclerosis pill Tecfidera is doing well, according to analyst Mark Schoenebaum of ISI. While it is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE